<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0346976" disease_type="Neoplastic Process" abbrv="">Pancreatic metastasis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is rare, and accounts for less than 2% of <z:hpo ids='HP_0000001'>all</z:hpo> pancreatic <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>There have been no studies that have reported the differences in the sensitivity to chemotherapy between the <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesion</z:e> and the <z:e sem="disease" ids="C0346976" disease_type="Neoplastic Process" abbrv="">pancreatic metastasis</z:e> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We experienced a rare example of <z:e sem="disease" ids="C0346976" disease_type="Neoplastic Process" abbrv="">pancreatic metastasis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and report here the difference in the sensitivity to the antitumor drug </plain></SENT>
<SENT sid="3" pm="."><plain>A 68-year-old female underwent colectomy for rectal <z:mp ids='MP_0002038'>carcinoma</z:mp> with a mass in the pancreatic tail and the liver </plain></SENT>
<SENT sid="4" pm="."><plain>The patient also underwent a distal pancreatectomy and a segmental liver resection at the same time </plain></SENT>
<SENT sid="5" pm="."><plain>v-Ki-ras2 Kirsten rat <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homolog (KRAS) and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> protein 53 (TP53) gene mutation analyses, in addition to the histopathological examinations, revealed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of the liver and the pancreatic tail as being <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from the primary <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>We employed a collagen gel droplet-embedded culture drug sensitivity test for both the <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesion</z:e> and the <z:e sem="disease" ids="C0346976" disease_type="Neoplastic Process" abbrv="">pancreatic metastasis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The sensitivity to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and FOLFOX (5-flurouracil, folinic acid and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>) were lower in the <z:e sem="disease" ids="C0346976" disease_type="Neoplastic Process" abbrv="">pancreatic metastasis</z:e> compared to the <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesion</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, <z:e sem="disease" ids="C0346976" disease_type="Neoplastic Process" abbrv="">pancreatic metastasis</z:e> from colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> is rare, and the present results suggest that there are potential differences in the sensitivity to chemotherapy between the primary <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> and its <z:e sem="disease" ids="C0346976" disease_type="Neoplastic Process" abbrv="">pancreatic metastasis</z:e> </plain></SENT>
</text></document>